All In Biotech

Drug Trial Radar · NCT04408638

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Feb 23, 2021

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

  • ObinutuzumabDrug

    Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.

  • GlofitamabDrug

    Participants will receive IV glofitamab for up to 12 cycles.

  • RituxumabDrug

    Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.

  • TocilizumabDrug

    Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).

  • GemcitabineDrug

    Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.

  • OxaliplatinDrug

    Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS), defined as the time from randomization to date of death from any causeTime frame: Up to 5 years

Locations

63 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Community Cancer Institute (CCI)

    Fresno, California

  • Baptist - MD Anderson Cancer Center

    Jacksonville, Florida

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Monash Health Monash Medical Centre

    Clayton, Victoria, Australia

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • CHU de Liège (Sart Tilman)

    Liège, Belgium

  • Peking University Third Hospital

    Beijing, China

  • Sun Yet-sen University Cancer Center

    Guangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Tianjin Cancer Hospital

    Tianjin, China

  • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • Zhejiang Cancer Hospital

    Zhejiang, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Aarhus Universitetshospital Skejby

    Aarhus N, Denmark

  • Rigshospitalet

    København Ø, Denmark

  • Institut Bergonie

    Bordeaux, France

  • Hopital Henri Mondor

    Créteil, France

  • Hopital Claude Huriez

    Lille, France

  • Chu de Montpellier-St Eloi

    Montpellier, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • CHU Pontchaillou

    Rennes, France

  • Universitatsklinikum Frankfurt

    Frankfurt, Germany

  • Universitätsklinikum Gießen und Marburg GmbH Standort Gießen Medizinische Klinik I

    Giessen, Germany

  • Universitaetsklinikum Regensburg

    Regensburg, Germany

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli

    Lublin, Poland

  • Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie

    Olsztyn, Poland

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.